Innohep and Hepatotoxicity aggravated - a phase IV clinical study of FDA data

Summary:

Hepatotoxicity aggravated is reported as a side effect among people who take Innohep (tinzaparin sodium), especially for people who are female, 30-39 old, have been taking the drug for < 1 month also take Atarax, and have Pain.

The phase IV clinical study analyzes which people have Hepatotoxicity aggravated when taking Innohep. It is created by eHealthMe based on reports of 9,220 people who have side effects when taking Innohep from the FDA, and is updated regularly.

What is Innohep?

Innohep has active ingredients of tinzaparin sodium. eHealthMe is studying from 9,243 Innohep users. Check the latest studies of Innohep.

What is Hepatotoxicity aggravated?

Hepatotoxicity aggravated (serious chemical-driven liver damage) is found to be associated with 925 drugs and 413 conditions by eHealthMe. Check the latest studies of Hepatotoxicity aggravated.

On Aug, 03, 2026

9,220 people reported to have side effects when taking Innohep.
Among them, 15 people (0.16%) have Hepatotoxicity aggravated.

Could Innohep cause Hepatotoxicity aggravated?

Among these 15 people:

How long have people been on Innohep when they have Hepatotoxicity aggravated? *

What is the gender of people who have Hepatotoxicity aggravated when taking Innohep? *

female: 64.29 %
male: 35.71 %

What is the age of people who have Hepatotoxicity aggravated when taking Innohep? *

What are other drugs people take besides Innohep? *

Trombyl: 5 people, 33.33%
Atarax: 5 people, 33.33%
Sorafenib: 3 people, 20.00%
Ranitidine: 3 people, 20.00%
Furosemide: 2 people, 13.33%
Morphine: 2 people, 13.33%
Paracetamol: 2 people, 13.33%
Decadron: 1 person, 6.67%
Fluconazole: 1 person, 6.67%
Erlotinib Hydrochloride: 1 person, 6.67%

What are other side effects people have besides Hepatotoxicity aggravated? *

Suicidal Ideation: 5 people, 33.33%
Ascites (accumulation of fluid in the abdominal cavity): 3 people, 20.00%
General Physical Health Deterioration (weak health status): 3 people, 20.00%
Hepatic Encephalopathy (spectrum of neuropsychiatric abnormalities in patients with liver failure): 3 people, 20.00%
Alanine Aminotransferase Increased: 2 people, 13.33%
Aspartate Aminotransferase Increased: 2 people, 13.33%
Colitis Ischaemic (due to infection of intestine impaired blood supply to colon): 1 person, 6.67%
Dizziness: 1 person, 6.67%
Depressed Level Of Consciousness: 1 person, 6.67%
Cough: 1 person, 6.67%

What are the existing conditions these people have? *

Pain: 4 people, 26.67%
Oedema (fluid collection in tissue): 2 people, 13.33%
Hepatic Neoplasm Malignant (liver cancer): 2 people, 13.33%
Constipation: 2 people, 13.33%
Ascites (accumulation of fluid in the abdominal cavity): 2 people, 13.33%
Pulmonary Embolism (blockage of the main artery of the lung): 1 person, 6.67%
Nausea And Vomiting: 1 person, 6.67%
Malignant Melanoma (skin cancer rises from melancytes): 1 person, 6.67%
Lung Neoplasm Malignant (cancer tumour of lung): 1 person, 6.67%
Lung Cancer - Non-Small Cell (lung cancer): 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Innohep and have Hepatotoxicity aggravated?

- Check whether Hepatotoxicity aggravated is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Innohep:

Innohep (9,243 reports)

Browse all side effects of Innohep:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hepatotoxicity aggravated:

Hepatotoxicity aggravated (925 drugs)

Browse all the conditions that are associated with Hepatotoxicity aggravated:

Hepatotoxicity aggravated (413 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on tinzaparin sodium (the active ingredients of Innohep) and Innohep (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.